Nalaganje...

RANKL Inhibition Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta

Recently, a new class of agents targeting the receptor activator of nuclear factor-κB ligand (RANKL) pathway has been developed for the treatment of osteoporosis and other bone diseases. In the current study, inhibition of the RANKL pathway was evaluated to assess effects on “bone quality” and fract...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Bargman, Renee, Huang, Alice, Boskey, Adele L., Raggio, Cathleen, Pleshko, Nancy
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2962883/
https://ncbi.nlm.nih.gov/pubmed/20053133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/03008200903108472
Oznake: Označite
Brez oznak, prvi označite!